DURECT reports Q1 net loss $7.6M; FDA supports single pivotal trial for larsucosterol in AH

DURECT CORP

2024-Q1 EPS reported -$0.25 revenue$1,827,000

FDA feedback supports single pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis; NDA filing possible if successful.
Q1 2024 total revenues $1.8M, net loss $7.6M vs revenues $2.1M, net loss $12.0M in Q1 2023.
Cash and investments $21.6M at Mar 31, 2024, down from $29.8M at Dec 31, 2023; debt $14.6M.
Late-breaking oral presentation of AHFIRM Phase 2b data accepted at EASL Congress 2024 in June.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DURECT CORP reported three months ended March 31, 2024 results: revenue $1.8 million, net income $7.6 million.

Period: three months ended March 31, 2024
Revenue: $1.8 million
Net income: $7.6 million
Result: reported results

Exact text from the filing

2b AHFIRM trial, which evaluated the safety and efficacy of larsucosterol as a treatment for patients with severe AH. Financial Highlights for Q1 2024: • Total revenues were $1.8 million and net loss was $7.6 million for the three months ended March 31, 2024 compared to total revenues of $2.1 million and net loss of $12.0 million for the three months ended March

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-058675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.